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ABSTRACT 
 
 
Charles University in Prague 
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Title of diploma thesis: The role of TAK1 in neuronal survival 
 
 
 
Transforming growth factor-β activated kinase-1 (TAK1) is a serine/threonine kinase 
and it is part of the mitogen-activated protein kinase (MAPK) signaling. TAK1 is a key 
modulator of the transcription factors NF-κB and AP1. Recent studies have shown that 
TAK1 is essential for the survival of different cell types. Here, we focus on the 
biological role of TAK1 in neurons in vivo. We used DAB immunohistochemistry to 
evaluate the effect of TAK1 in neuronal survival. Therefore we compared the number of 
neurons in TAK1 knockout mice and TAK1fl/fl control mice. However, we did not find 
any significant difference in the number of neurons between both groups of mice. 
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TAK1 je serin/threoninová kináza, která je členem proteinové rodiny MAPK. TAK1 je 
klíčový modulátor transkripčních faktorů NF-κB a AP1. Nedávné studie prokázaly, že 
TAK1 je nezbytný pro přežití určitých typů buněk. V této práci jsme se zaměřili na 
biologickou roli proteinu TAK1 pro přežití neuronů. Porovnávali jsme počet neuronů u 
geneticky upravených myší, kterým chybí TAK1 s počtem neuronů u kontrolních myší. 
Avšak, nenašli jsme podstatný rozdíl počtu neuronů mezi oběmi skupinami myší. 
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ABBREVIATIONS 
 
°C                           degree Celsius 
AP1                        activator protein 
IKK                        IκB kinase complex 
IL-1                        interleukin-1 
IL-1βR                   interleukin-1 receptor 
IκB                         inhibitor of kappa B 
JNK                        c-Jun NH2-terminal kinase 
MAPK                    mitogen-activated protein kinase 
NEMO                    nuclear-factor-kappa-beta essential modulator 
NF-κB                    nuclear-factor-kappa-beta 
RHD                       REL-homology domain 
RIP1                       receptor interaction protein 1 
SDS-PAGE            sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TAB1                     transforming growth factor-β activated kinase-1 bindings protein 1 
TAB2                     transforming growth factor-β activated kinase-1 bindings protein 2 
TAB3                     transforming growth factor-β activated kinase-1 bindings protein 3 
TAK1                     transforming growth factor-β activated kinase-1 
TGF-β                     transforming growth factor-β 
TLR                        toll like receptor 
TNF                        tumor necrosis factor 
TRADD                  TNF receptor-associated death domain protein 
TRAF2                   TNF receptor associated factor 2 
TRAF5                   TNF receptor associated factor 5 
TRAF6                   TNF receptor associated factor 6 
TβRI                       TGF-β type I receptor 
TβRII                      TGF-β type II receptor 
UV                          ultraviolet 
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1. INTRODUCTION 
 
1.1. Stroke 
 
Stroke is the third leading cause of death in the United States (Nestler et al.2009). It is a 
worldwide problem and causes vast medical, economical and personal costs.  
Stroke, also known as cerebrovascular accident, occurs when blood flow to the brain is 
interrupted. It is either caused by obstruction or hemorrhage. The brain loses its energy 
supply, which results in oxygen and glucose deprivation. Since neurons are vulnerable 
to energy deprivation this can lead to a complete loss of function within ten seconds 
(Nestler et al.2009).  
 
1.2. Neuronal cell death  
 
Due to deprivation of essential nutrients neurons enter a stress state and the membrane 
potential breaks down. When neurons depolarize they transmit action potentials and 
within this reaction they release glutamate into the synaptic cleft. This initiates 
a destructive cycle of activation of neighboring cells and further glutamate release. Due 
to the excitotoxic effect of this self-enhancing glutamate release, ion gradients disrupt, 
calcium flows into the cell, the cells swell, mitochondrial membranes get damaged, 
cellular proteases and lipases get activated and free radicals accumulate. Finally, all 
these processes will result in the death of the neuron (Nestler et al.2009).  
Depending on the strength of the harmful stimulus during ischemia, neurons will either 
die by a programmed cell death, called apoptosis or by cellular disruption, called 
necrosis. The infarct area after ischemia can be divided in two major zones, the 
infarct core, where blood supply is cut almost completely and cells receive a very 
harmful stimulus that will induce necrosis and the surrounding area, the so called 
penumbra where cells receive a milder stimulus and may enter apoptosis (Nestler et 
al.2009).   
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1.2.1. Necrosis 
 
In response to cellular stress, such as ischemia, UV irradiation, free radicals, toxins, 
neurons activate intracellular stress pathways. When neurons receive excessive injury, 
these pathways are over-activated. The resulting necrotic neurons and their organelles 
swell, or burst. Necrosis is known for the leakage of cytoplasmatic and organelle 
contents into the extracellular space. This might be toxic to neighboring cells and can 
lead to inflammation. Necrosis is always a detrimental process (Nestler et al.2009). 
 
1.2.2. Apoptosis 
 
Apoptosis is a process of programmed cell death. It is already important during 
development of nervous system, because it causes pruning of excess neurons and 
corrects connections between nerve cells. On the other hand, apoptotic mechanisms of 
neuronal death contribute to neurodegenerative disorders (Nestler et al.2009). 
Apoptotic neurons are subjected to a series of tightly regulated processes. Unlike 
necrosis, during apoptosis potentially dangerous intracellular material can safely be 
liquidated. Such material is packaged into vesicles, released and can be taken up by 
endocytosis and metabolized by surrounding cells. Apoptosis is an active process and 
results from the execution of a well-regulated genetic program.    
Deleterious effect of apoptosis can be induced by activation of stress-activated protein 
kinases like c-Jun NH2-terminal kinase (JNK) or p38/MAPK (Nestler et al.2009). Also 
Nuclear-factor-kappa-beta (NF-κB) has been shown to be a primary regulator of 
programmed cell death. NF-κB is well known for its anti-apoptotic function (Barkett 
and Gilmore 1999; Dutta et al. 2006). However, there is also evidence for its pro-
apoptotic action (Qin et al. 1999; Pizzi et al. 2002). Transforming growth factor-β 
activated kinase-1 (TAK1) is an upstream signal of JNK, p38/MAPK and NF- κB and 
might therefore play a role in regulation of apoptosis. 
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1.3. Transforming growth factor-β activated kinase-1  
 
The serine/threonine kinase Transforming growth factor-β activated kinase-1 (TAK1) is 
a member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family and 
is involved in many signaling pathways in cells (Yamaguchi et al. 1995). 
Activity of TAK1 requires its binding proteins TAB1, TAB2 and TAB3 (Shibuya et al. 
1996; Takaesu et al. 2000; Cheung et al. 2003; Ishitani et al. 2003).  
TAB1 and TAB2 proteins were identified in a yeast two-hybrid screen. TAB1 can 
activate TAK1 directly in vitro. It has been shown, that TAB1 enhances TAK1 kinase 
activity when co-expressed. TAB1 binds specifically to TAK1 (Shibuya et al. 1996) and 
induces autophosphorylation of TAK1 (Kishimoto et al. 2000). The role of TAB1 was 
investigated in different signaling pathways upstream of TAK1. TAB1 is dispensable 
for tumor necrosis factor- (TNF) and interleukin- (IL) induced activation of TAK1. 
Association of TAB1 and TAK1 is important for osmotic stress-induced activation of 
TAK1 (Inagaki et al. 2008).  
TAB2 links TAK1 to TNF receptor associated factor 6 (TRAF6) and thereby mediates 
TAK1 activation in response to IL-1 (Takaesu et al. 2000). TAB3 mediates interaction 
of TAK1 with TRAF2 and TRAF6 in an IL-1 and TNF-dependent manner (Ishitani et 
al. 2003). Activation of the TAK1/TAB2 (or TAB3) complex requires K63-linked 
polyubiquitination in the presence of ubiquitin-conjugating enzyme E1, E2 (Ubc13 and 
Uev1A) and E3 (TRAF6) (Wang et al. 2001) 
Taken together, TAB2 and its close homologue TAB3, unlike TAB1, does not activate 
TAK1 directly in vitro. Nevertheless, TAB2 and TAB3 play a critical role in activation 
of the IL-1- and TNF-induced NF-κB pathway, JNK and p38/MAPK (Ishitani et al. 
2003).  
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1.4. TAK1-signalling pathways  
 
TAK1 was originally identified as a kinase involved in transforming growth factor beta 
(TGF-β) signaling pathway and a regulator of bone morphogenetic protein signals 
(Yamaguchi et al. 1995). Stimulation of cells with pro-inflammatory cytokines such IL-
1β and TNF initiates a cascade of signaling pathways, including activation of NF-κB 
and MAPKs such as c-Jun NH2-terminal kinase (JNK) and p38/MAPK. It induces 
the expression of genes in the nucleus that regulate inflammation (Dinarello 1996). As 
shown in Figure 1, TAK1 was found to be a crucial regulator of these pathways 
(Ninomiya-Tsuji et al. 1999; Takaesu et al. 2000; Wang et al. 2001).  
 Under physiological conditions, TAK1 is associated with transforming growth factor-β 
(TGF-β) type I receptor (TβRI) through a complex with TAB2 and the ubiquitin ligase 
TRAF6. Upon TGF-β stimulation, TβRI and TβRII form a heterotetrameric comlex, 
which leads to autopolyubiquitination of TRAF6 and subsequent polyubiquitination of 
TAK1.  TAK1 in turn dissociates from TβRI. After release of TAK1 from receptor 
complex, TAK1 interacts with TAB1, which induces autophosphorylation of TAK1 
(Kim et al. 2009). Then, TAK1 triggers downstream signaling cascades, including 
MAPK kinase (MKK) 4/7- JNK cascade, MKK 3/6-p38/MAPK cascade and activation 
of NF-κB (Kishimoto et al. 2000). JNK and p38/MAPK control activation of the 
transcription factor activator protein (AP1) (Chen and Goeddel 2002). 
Stimulation of IL-1β receptor1β (IL-1βR) and toll like receptor (TLR) leads to 
activation of TRAF6. TRAF6 causes K-63 polyubiquitination (Deng et al. 2000), which 
leads to activation of TAK1 kinase complex. TAK1 activates IκB kinase (IKK) complex 
(Wang et al. 2001) that in turn phosphorylates the IκB proteins and thereby targets this 
inhibitor of NF-κB activity for proteosomal degradation. Now, free NF-κB can enter the 
nucleus and modulate target gene expression (Scheidereit 2006).  
In the TNF pathway, binding of TNF to its receptor leads to the recruitment of signal 
proteins such as TRADD, TRAF2, TRAF5, and receptor interaction protein 1 (RIP1). 
Polyubiquitinated RIP1 is essential for TNF signaling and recruits IKK through the 
interaction between polyubiquitin chains and NEMO (Ea et al. 2006). 
Polyubiquitination of RIP1 recruits the TAK1 complex through the interaction between 
polyubiquitin chains and TAB2 or TAB3 (Kanayama et al. 2004). It allows TAK1 to 
phosphorylate IKK and thus induce activation of NF-κB (Wang et al. 2001). 
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Figure 1:  A model of TAK1 activation by stimulation of TGF receptor, IL-β 
receptor/Toll like receptor and TNF receptor 
Exposure of cells to growth factors, pro-inflammatory cytokines leads to activation of 
specific ubiquitin ligases, which promote K-63 polyubiquitination. In case of TGFR, K-
63 polyubiquitination attracts TAB2/3, which promotes activation of TAK1. TAK1 can 
phosphorylate MKK in the JNK, p38/MAPK pathway. JNK and p38/MAPK control the 
transcription factor AP-1.  
Stimulation of IL-1βR/TLR leads to activation of TAK1. TAK1 then phosphorylates 
IKK complex that in turn phosphorylates IκB and targets this inhibitor for proteosomal 
degradation. Free NF-κB can enter the nucleus to modulate target genes.  
Stimulation of TNFR leads to activation of TRAF2, TRAF5, which then promote K-63 
polyubiquitination of RIP1. Polyubiquitination of RIP1 recruits TAK1 complex through 
the interaction between polyubiquitin chains and TAB2 or TAB3. The polyubiquitin 
chains also recruit IKK by binding to NEMO. This allows TAK1 to phosphorylate IKK 
and activate NF-κB. 
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1.5. The NF-κB signaling pathways 
 
 NF-κB is a key transcription factor that regulates biological processes including 
immunity, inflammation and apoptosis (Skaug et al. 2009). The NF-κB family of 
transcription factors consists of p50, p52,  p65 (REL-A), c-REL, REL- B (for review, 
see Hayden and Ghosh 2008).  These subunits form homo- and heterodimers in various 
combinations.  
In the canonical pathway, NF-κB is activated by TNF, IL-1β, and TLR ligands that are 
recognized by specific membrane receptors. Stimulation of these receptors leads to 
activation of the TAK1 complex through TRAF proteins. TAK1 then activates IκB 
kinase complex (IKK), consisting of the two enzymatic subunits IKK1 (IKK-α) and 
IKK2 (IKK-β), and the regulatory subunit NF-κB essential modulator (NEMO) (Skaug 
et al. 2009). IκB (inhibitor of kappa B) proteins are bound to NF-κB dimers and retain 
the dimers in the cytosol. All IκB proteins are characterized by presence of ankyrin 
repeat domains that bind to NF-κB dimers. The N-terminal REL-homology domain 
(RHD), which is contained in all of the NF-κB family members, is responsible for 
homo- and heterodimerization, DNA binding, nuclear translocation, and interaction 
with IκB proteins (Skaug et al. 2009). Upon activation IKK phosphorylates IκB-α at 
serines 32 and 36, induces polyubiquitination of lysines 21 and 22 and finally 
degradation by the 26S proteasome (Chen 2005).  After degradation of IκB, free NF-κB 
translocates into the nucleus and triggers gene transcription (for review, see Ridder and 
Schwaninger 2009).  
NF-κB induces gene transcription of Bcl-2 family members with opposite effects, i.e. 
either pro-apoptotic (Bim, Noxa) (Inta et al. 2006) or anti-apoptotic (Bcl-2 and Bcl-XL) 
(Tamatani et al. 1999). It has been shown, that NF-κB is activated in cerebral ischemia 
(Mattson and Camandola 2001; Inta et al. 2006). Pro-apoptotic Bcl-2 family members, 
Bim and Noxa, are up-regulated in cerebral ischemia. Interestingly, conditional deletion 
of RelA in neuronal cells or pharmacological inhibition of IKK blocked Bim and Noxa 
gene expression (Inta et al. 2006). On the other hand, protective effects of NF-κB may 
be mediated by c-Rel (Pizzi et al. 2002) Thus gene transcription regulates the ratio of 
pro-apoptotic and anti-apoptotic Bcl-2 family members.  
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1.6. The role of TAK1 and its binding proteins in cell survival  
 
TAK1-deficiency results in developmental abnormalities in the neuronal tube and 
embryonic death at day E9.5. This strongly suggests a critical role of TAK1 in early 
embryonic development (Shim et al. 2005). However, the phenotype of TAK1-deficient 
embryos is different from that of TAB1 and TAB2-deficient embryos. TAB1 mutant 
embryos die at a late stage of gestation due to failures in cardiovascular and pulmonary 
morphogenesis (Komatsu et al. 2002) and TAB2 mutant embryos die around embryonic 
day 12.5 due to liver apoptosis (Sanjo et al. 2003). 
It has been shown that TAK1 is critical for the survival of both, hematopoietic cells and 
hepatocytes. Deletion of TAK1 results in bone marrow and liver failure due to apoptotic 
death of hematopoietic cells and hepatocytes. Furthermore, deletion of TAK1 results in 
inactivation of NF-κB and JNK signaling (Tang et al. 2008). 
It has been reported that following activation by TNF and IL-1, mouse embryonic 
fibroblasts from TAK1-null mice exhibit decreased NF-κB and JNK activation. These 
cells are highly sensitive to TNF-induced apoptosis (Shim et al. 2005), whereas 
activation of NF-κB following TNF stimulation is required for protection of cells from 
TNF-induced cell death (Beg and Baltimore 1996; Van Antwerp et al. 1996). The 
conditional knockout system was used to delete RelA/p65 in the liver. In these mice 
hepatocyte apoptosis is induced upon stimulation with TNF (Geisler et al. 2007).  
TAK1 is known to be critical for keratinocyte survival, since epidermal-specific 
deletion of TAK1 results in massive keratinocyte death due to sensitization to TNF-
induced apoptosis. These cells fail to activate NF-κB or JNK upon TNF treatment. This 
suggests, that NF-κB and JNK play an important role in survival signaling upon TNF-
induced apoptosis (Omori et al. 2006).  
Taken together these studies confirm that NF-κB and JNK play a role in cell survival 
both after treatment with TNF and in the absence of any cytokine treatment. It has 
previously been demonstrated that NF-κB and JNK induce expression of both pro-
apoptotic and pro-survival genes (Middleton et al. 2000; Pizzi et al. 2002; Liu and Lin 
2005). There is evidence that both JNK and NF-κB are present in neurons (Wang et al. 
2004; Zhang et al. 2005). To investigate whether TAK1 plays an important role in 
neuronal survival, we generated transgenic mice that were deficient for TAK1 in 
neurons.  
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1.7. Cre-lox system 
 
Transgenic technology is an important tool for investigating individual gene function. 
Cre-lox recombination is a special type of site-specific recombination. This system was 
discovered in P1 bacteriophage. Cre-lox system can delete undesired DNA sequences. 
It requires two components, first the Cre recombinase, an enzyme that catalyzes 
recombination between two loxP sites and additionally the loxP recognition sites (locus 
of X-over P1), consisting of 34 base pairs (8-base-pair core sequence flanked by 13-
base-pair inverted repeats) (Sauer and Henderson 1988).  
Cre recombinase is expressed under a tissue specific promoter. Mice carrying Cre 
recombinase are crossed with mice carrying loxP-flanked gene. The gene for Cre 
recombinase and loxP sites must be introduced to the mouse genome by transgenic 
technology (Nagy 2000) . 
Cre recombination can induce a deletion, inversion, or chromosomal translocation 
depending on the orientation and location of the loxP sites. To induce deletion of target 
genes, loxP sites are required to be oriented in the same direction on a chromosomal 
segment (Nagy 2000) (Figure 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Orientation of loxP sites for deletion of target genes 
Deletion of target genes occurs when loxP sites are oriented in the same direction on 
a chromosomal segment (www.jax.org). 
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2. AIM OF WORK 
 
In this study we focus on the biological role of TAK1 in neurons in vivo.  
In order to study the function of TAK1 in neurons, a transgenic mouse was generated 
that was deficient for TAK1 in neurons. Since global TAK1 deletion is embryonically 
letal, a conditional knockout strategy was chosen. Therefore TAK1fl/fl mice (Sato et al. 
2005) were crossed with mice carrying the Cre recombinase under the promoter of 
CamKinase-II alpha (CamKII-a-Cre) (Casanova et al. 2001). CamKinase-II alpha 
promoter is expressed postnatally (Burgin et al. 1990). This strategy resulted in the 
generation of mice in which the floxed Exon II of the TAK1 gene was specifically 
deleted in neurons after birth. 
We evaluated the effect of TAK1 on neuronal survival by comparison of the number of 
neurons in TAK1 knockout mice and TAK1fl/fl control mice. 
To determine whether TAK1 deletion has an impact on neuronal survival, we 
investigated neurons in two different areas of the brain, the cerebral cortex and the 
hippocampus. 
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3. MATERIALS AND METHODS 
 
3.1. Materials 
 
3.1.1. Animals 
 
We used sixteen to twenty-seven-week-old age- and sex-matched male and female mice 
(Table 1). TAK1fl/fl mice were crossed with CamKII-alpha-Cre (CKC-cre) mice 
(Casanova et al. 2001). Half of the animals used for this study were positive for the 
CKC-cre allele (TAK1nko) and CKC-cre negative littermates (TAK1fl/fl) were taken as 
controls. All lines were backcrossed on a C57Bl/6 background. 
 
Table 1: Mice of the experiment 
 
 MALE FEMALE 
TAK1 neuronal knockout mice 
(TAK1nko) 10 7 
TAK1 floxed-control mice 
(TAK1fl/fl) 12 5 
 
3.1.2. Material 
 
• Conical test tube PP (NP Nerbe Plus, Winsen/Luhe, GE) 
• Cover slips (Carl Roth, Karlsruhe, GE) 
• Fat pen (Dako Deutschland, Hamburg, GE) 
• Microtube 1,5 ml (Sarstedt, Nümbrecht, GE) 
• Pasteur pipette (Neolab, Heidelberg, GE) 
• Pipette (Gilner Geiner Bio-One, Frickenhausen, GE) 
• Pipette tips (Gilner Geiner Bio-One, Frickenhausen, GE) 
• Polysine slides (Menzel Gläser, Braunschweig, GE) 
• Serological pipette 5ml, 10 ml, 25 ml (Sarstedt, Nümbrecht, GE) 
• Staining dish (Neolab, Heidelberg, GE) 
• Tissue freezing medium (Jung, Nussloch, GE) 
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3.1.3. Instruments 
 
• Leica cryotome CM 3050S (Leica, Mannheim, GE) 
• Microscope leica DM LS2 (Leica, Mannheim, GE) 
 
3.1.4. Chemicals 
 
• Albumin fraktion V. (Carl Roth, Karlsruhe, GE) 
• Distilled water (IPMB, GE)  
• Glycerol anhydrous (AppliChem GmbH, Darmstadt, GE) 
• H2O2 30% (CARL ROTH, Karlsruhe, GE) 
• HCl fuming 37% (Merck KGaA, Darmstadt, GE) 
• Horse serum (Invitrogen, Karlsruhe, GE) 
• KCl (AppliChem GmbH, Darmstadt, GE) 
• KH2PO4 (Grüssing GmbH, Filsum, GE) 
• Methanol 100% (J.T.Baker, Deventer, NL) 
• Mowiol 488 (Carl Roth, Karlsruhe, GE) 
• Na2HPO4 x 2 H2O (AppliChem GmbH, Darmstadt, GE) 
• NaCl (VWR International GmbH, Darmstadt, GE) 
• Paraformaldehyde (Sigma-Aldrich, Seelze, GE) 
• Sucrose (Applichem, Darmstadt,GE) 
• Triton X-100 (Merck, Darmstadt, GE) 
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3.1.5. Stock solution   
 
PBS 10x 
• 80.0 g NaCl 
• 2.0 g KCl 
• 18 g Na2HPO4 x 2H2O 
• 2.4 g KH2PO4 
• Add up 1000 ml with dH2O 
• Adjust pH to 7.4 
 
1x PBS 
•  100.0 ml PBS 10x 
•  Add up 1000 ml with dH2O 
 
3.1.6. Antibodies 
 
• Anti-mouse biotinylated IgG (H+L), made in horse ( Vector Laboratories, CA 
94010, Lot: NO 923, Burlingame, CA) 
• MsX NeuN MAB377 (Chemicon, CA 92 590, Lot: LV 1427917 , Temecula, 
USA) 
 
3.1.7. Kits 
 
• ABC Kit-Vectastain, Peroxidase standard (Vector Laboratories, Burlingame, 
CA) 
• DAB Kit-Peroxidase Substrate Kit (Vector Laboratories, Burlingame, CA) 
 
 22 
3.1.8. Imagine software 
 
• Adobe Photoshop CS2 
• Graph Pad Prism 
• ImageJ 
• Microsoft Office 
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3.2. Methods 
3.2.1. Protein Analysis  
3.2.1.1. SDS-PAGE analysis of proteins 
 
To separate proteins of cell lysates, we performed Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). First, brains were isolated from the 
mouse. Then, cortex and cerebellum were isolated and immediately frozen on dry ice. 
Tissues were pestled on dry ice. SDS-sample buffer was added and samples were 
incubated for five min at 95°C, cooled down on ice and equally loaded onto a SDS-
polyacrylamide gel with an acrylamide concentration of 8%. Gel electrophoresis was 
done at 100V.  
 
3.2.1.2. Western Blot analysis 
 
In order to detect a specific protein in a cell lysate, after separation of proteins by charge 
and size using SDS-PAGE, we blotted proteins onto a nitro-cellulose membrane. The 
membrane was equilibrated in blotting buffer and subsequently proteins were blotted 
onto the membrane at 300 mA for two hours in a wet-blot chamber.  
Membrane was shortly washed in TBS-T and blocked in 5 % milk in TBS-T. Then 
membrane was washed three times for five minutes in TBS-T, following incubation in 
the first antibody (either anti-TAK1 or anti-tubulin) over night at 4°C. The next day 
membranes were washed three times for five minutes in TBS-T and then incubated for 
one hour at room temperature with the secondary anti-rabbit antibody (1:5000) in 5 % 
milk. Membrane was washed three times for five minutes in TBS-T. For detection, the 
membranes were exposed to enhanced chemiluminescence solution for one minute and 
then exposed to a film in the dark room. 
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3.2.2. Tissue preparation 
 
• ANESTHESIA 
 
Mice were anesthetized by injecting intraperitoneally 20 µl/g bodyweight of 
avertin. To confirm whether mice were anesthetized paw-reflex was tested.  
 
• TRANSCARDIAL PERFUSION 
 
After cutting off the muscle and bone to uncover the heart a small incision was 
made in the right ventricle of the heart and the mouse was perfused through left 
ventricle with 5 ml Ringer solution until the liver became white. Initially we 
started the experiment by subsequent perfusion of mice with 4% 
paraformaldehyde (PFA). After evaluation of cryosections this step was 
eliminated in further experiments due to morphological changes. 
 
• DISSECTION OF THE BRAIN 
 
Starting the experiment we dissected the brains and incubated them in PBS for 
1h followed by incubation in 10% sucrose in PBS for 1h and 20% sucrose for 1h 
and finally in 30 % sucrose overnight. After evaluation of cryosections this step 
was modified such that brains were immediately frozen on dry-ice after 
dissection and frozen at -20 °C (for detailed overview on individual treatment 
see table below). 
 
• CUTTING THE BRAINS 
 
The brains were cut with a cryotome at -22°C to -25°C. Sections had a thickness 
of 20 µm and were collected on poly-lysine-coated-slides and subsequently 
stored at -20°C. 
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Table 2.:  Individual treatment of the brains after dissection. 
Mouse-line numbers refer to the mouse line in the mouse keeping unit: 0987: TAK1; 
0918: TAK1-flox; 1193: TAK1-ZNSKO.  
 
 
 
 
 
MOUSE-
LINE NAME 4% PFA IN PBS SUCROSE DRY ICE 
918 37 X X  
918 62 X X  
918 102  X  
918 103  X  
987 446   X 
987 447   X 
1193 140   X 
1193 143   X 
1193 150   X 
1193 152   X 
1193 173   X 
1193 174   X 
1193 175   X 
1193 183 X X  
1193 184 X X  
1193 192  X  
1193 193  X  
1193 194  X 
 
1193 197  X 
 
1193 198  X 
 
1193 199   X 
1193 200   X 
1193 201  X 
 
1193 202  X 
 
1193 203  X 
 
1193 204   X 
1193 205   X 
1193 206   X 
1193 209   X 
1193 210   X 
1193 211   X 
1193 212   X 
1193 213   X 
1193 219   X 
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3.2.3. Immunohistochemistry staining  
 
3.2.3.1. Staining for NeuN with DAB 
 
Slides were dried at room temperature for fifteen minutes and sections were surrounded 
with a fat- pen. Then slides were delipidate with 100% CH3OH for ten minutes at -
20°C. After drying at room temperature for about twenty minutes slides were rinsed 
three times for ten minutes in PBS. To block endogenous peroxidase activity slides 
were rinsed with 2% H2O2/10% CH3OH/PBS for twenty minutes at room temperature. 
Afterwards sections were washed three times for ten minutes in PBS. Sections were 
permeabilized in 0.4 % Triton X-100/PBS for one hour and then blocked with 1.5 % 
horse serum/1% BSA/0.1% Triton X-100/PBS for one hour at room temperature. Then 
sections were incubated with anti-NeuN monoclonal antibody (1:1000 in 0.1% Triton 
X-100/1% BSA/PBS) at 4°C overnight. After that, sections were washed three times for 
ten minutes in PBS and incubated with secondary anti-mouse biotinylated IgG (1:50) in 
2% horse serum/PBS. Then peroxidase-labeled avidin-biotin complex was incubated for 
thirty minutes. The ABC complex was prepared by mixing 2.5 ml PBS and 1 drop 
solution A and 1 drop solution B followed thirty minutes of incubation. Afterwards 
slides were washed three times for ten minutes in PBS. Sections were rinsed with DAB 
solution, which consist of 2.5ml distilled water with 1 drop buffer, 2 drops DAB, 1 drop 
hydrogen peroxide. DAB solution was applied until sections became dark. To stop DAB 
reaction, slides were washed with PBS for ten minutes and mounted with coverslips 
using Mowiol. Mowiol mounting medium consists of 2.4 g Mowiol 4-88/6.0g 
glycerol/6.0ml distilled water/12 ml 0.2 M Tris-HCl (pH 8.5). 
 
 
3.2.4. Evaluation of cell number 
 
Stained sections were photographed using a microscope at 5x or 10x magnification. 
Images were edited using the software Adobe Photoshop CS2. Brain structures were 
identified by overlapping the individual sections with a contour of a model section from 
a brain-atlas library (www.brain-map.org). This method assured that identical sections 
and brain-areas were evaluated. Cells were counted manually using the software ImageJ 
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and the cell counter Plug-in. Results were analyzed and statistically evaluated using 
Microsoft Excel and Graph Pad Prism. 
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4. RESULTS 
 
 
4.1. Protein Analysis 
 
 
In order to study the impact of TAK1 on neuronal survival in vivo we used a mouse line 
with a neuron specific deletion of the TAK1 gene (TAK1nko) and control mice 
(TAK1fl/fl).  First we determined protein level of TAK1 in the cortex and cerebellum of 
both lines by Western Blot analysis and found a strong reduction of TAK1 protein level 
in the cortex of TAK1nko mice (Fig. 3) compared to TAK1fl/fl mice. The CaMKIIalpha 
promoter is not active in the cerebellum. We found no difference in the protein level of 
TAK1 in lysates of the cerebellum.  
 
tubulin
TAK1
Cre +-+-
Cortex Cerebellum
 
 
Figure 3: TAK1 protein is absent in the cortex, but not in the cerebellum of 
TAK1nko mice 
Western Blot of protein lysates from mouse cortex or cerebellum. The protein levels of 
TAK1 in mice that express the Cre recombinase (+) under the CaMKII-alpha promoter 
(TAK1nko) were compared to those not expressing Cre (-) (TAK1fl/fl). Same loading of 
the samples was controlled by detection of tubulin protein levels on the same 
membrane.  
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4.2. Cerebral cortex 
 
 
In order to analyze the impact of TAK1 on neuronal survival, we sought to quantify the 
amount of neurons in brains of TAK1nko and control mice. Since neurons specifically 
express the nuclear protein NeuN (Mullen et al. 1992) we used immunohistochemistry 
of NeuN to label neurons. A reference section from brain-atlas was taken and compared 
to cryosections of test mice (Fig.4, 5). 
Quantification of neurons in the cortex at the level of section number 47 (number 
according to Paxinos Brain Atlas) revealed no difference in the numbers of neurons of 
TAK1nko and control mice (Fig. 6). All layers of the cortical sections were analyzed 
individually and no significant difference in neuronal numbers was observed. However, 
we found a trend that Cre+ mice seem to have lower number of neurons in all layers.  
Additionally, we compared the total number of neurons in a determined area of the 
cortex and observed huge variation in the number of neurons in between the groups. 
Although Cre+ mice have lower number of neurons, no significant difference is 
observed between both groups (Fig. 7).  
To evaluate whether the number of neurons in the individual layers between both, Cre- 
and Cre+ mice are different, we tested the groups in 2-way ANOVA (Figure 8). No 
significant difference was found between the individual layers and groups. 
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A. 
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
Figure 4.  Used section for counting of neurons in cortex 
(A) Model section from brain-atlas with contour of layers. (B) Stained section with anti-
NeuN antibody (1:1000) and DAB solution. The cortex is overlapped with contour of 
a model section – number 47 according to Paxinos Brain Atlas). The neurons were 
counted in area of rectangle. 
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Figure 5.  Example of stained section with antibody anti-NeuN (1:1000) by 5x 
magnification 
DAB immunohistochemistry was used to visualize the neurons in cortex. The neurons 
were stained by using the anti-NeuN antibody (1:1000). Region of cortex is divided in 
Layer I, Layer II/III, Layer IV, Layer V, Layer VIa and Layer VIb. The neurons were 
counted in area of rectangle. 
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A.                                                                       B. 
 
 
 
 
 
 
 
 
 
 
 
 
C.                                                                       D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Number of NeuN-positive cells in individual layers of the cortex 
Cre- represents TAK1fl/fl control mice and Cre+ represents TAK1nko mice. Sections 
corresponding to section number 47 in the Paxinos Brain Atlas were stained  for NeuN 
by DAB immunohistochemistry and quantified using ImageJ software. Statistic was 
performed using Students t-test A. p= 0.5282, B. p =0.3822 C. p=0.3591 D. p=2718. No 
significant difference was observed between the layers of Cre- (n=10) and Cre+ (n=9) 
male and female mice.  
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Figure 7. Number of NeuN-positive cells in all layers of cortex 
Cre- represents TAK1fl/fl control mice and Cre+ represents TAK1nko mice. The 
cryosections of brains were stained for NeuN  by DAB immunohistochemistry and 
counted using ImageJ software. Statistical analysis was performed using Students t-test. 
p=0.3246. No significant difference was observed in both Cre- (n=10) and Cre+ (n=9) 
male and female mice in all layers together.  
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Figure 8.  Number of NeuN-positive cells in individual layers of the cortex 
Cre- represents TAK1fl/fl control mice and Cre+ represents TAK1nko mice. The numbers 
of NeuN-positive cells were counted in the regions of cortex: Layer I/II/III, Layer IV, 
Layer V and Layer VI. These regions were defined by comparison with section number 
47 of the Paxinos Brain Atlas (note: region Layer IV is much smaller region than the 
other regions). Statistical analysis was performed using repeated measures-2-way 
ANOVA; Genotype: F(1,51)=1.03, p=0.3246; Layer: F(3,51)= 365.43, p<0.0001, no 
interaction. In each region of cortex measured for neuronal cells, no significant 
differences were observed in both the Cre+ (n=10) and the Cre-  (n=9) male and female 
mice. 
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4.3. Hippocampus 
 
 
In order to analyze the number of neurons in the hippocampus, we selected section 68 
of the Paxinos Brain Atlas and compared the number of neurons observed in the frame 
in the brains of TAK1nko and TAK1fl/fl mice.  
In accordance with brain-atlas, we divided the hippocampal area into three regions- 
CA1, CA2, CA3 (Fig. 9, 10).  
 
 
 
 
 
 
Figure 9. Example of stained section with antibody anti-NeuN (1:1000) by 10x 
magnification 
DAB immunohistochemistry was used to visualize the neurons in hippocampus. The 
neurons were stained by using the anti-NeuN antibody (1:1000). Region of 
hippocampus was divided into CA1, CA2 and CA3 regions in accordance with Paxinos 
Brain Atlas. The neurons were counted in area in red contour limited by blue line. 
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A. 
 
 
B. 
  
 
 
Figure 10. Example of brain section for counting of neurons of the hippocampus 
(A) Reference section from brain atlas. (B) Stained section with anti-NeuN antibody 
(1:1000) and DAB solution. The region of hippocampus is overlapped with a countour 
of a model section number 68 according to Paxinos Brain Atlas. 
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 Quantification of neurons in section number 68 (number according to Paxinos Brain 
Atlas) revealed no difference in the numbers of neurons of TAK1nko and control mice 
(Fig. 11). All layers of the cortical sections were analyzed individually and no 
significant difference in neuronal numbers was observed. In CA1 region Cre+ mice 
seem to have lower number of neurons, whereas in CA2 and CA3 region Cre- mice 
seem to have lower number of neurons. However, difference in number of neurons 
between both of groups is minimal. 
In addition, we compared the total number of neurons in a determined area of the 
hippocampus and observed huge variation in the number of neurons in between the 
groups. We found, that no significant difference is observed between both groups  
(Fig. 12). 
To evaluate whether the number of neurons in the individual regions between both, Cre- 
and Cre+ mice are different, we tested the groups in 2-way ANOVA (Figure 13). No 
significant difference was found between the individual layers and groups. 
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  A.                                                           B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Number of NeuN-positive cells in individual regions of the hippocampus 
Cre- represents TAK1fl/fl control mice and Cre+ represents TAK1nko. Neurons of 
hippocampal sections were stained for NeuN by DAB immunohistochemistry and 
quantified using ImageJ software. Statistic was performed using Students t-test.  
A. p=0.1869 B. p=0.7313 C. p=0.6806. No significant difference in single regions was 
observed in both Cre- (n=5) and Cre+ (n=5) female mice.  
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Figure 12 . Number of NeuN-positive cells in all regions of hippocampus 
Cre- represents TAK1fl/flcontrol mice and Cre+ represents TAK1nko. The cryosections of 
brains were stained for NeuN by DAB immunohistochemistry and counted using 
ImageJ software. Statistical analysis was performed using Students t- test. p=0.9027. No 
significant difference was observed in both Cre- (n=5) and Cre+ (n=5) female mice in 
all regions together.  
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Figure 23. Nummer of NeuN-positive cells in each anatomical region of the 
hippocampus. 
Cre- represents TAK1fl/fl control mice and Cre+ represents TAK1nko mice. The numbers 
of NeuN-positive cells were counted in the CA1, CA2 and CA3 regions. These regions 
were defined by comparison with section number 47 of the Paxinos Brain Atlas  
(note: region CA2 is a much smaller region than CA1 and CA3). Statistical analysis was 
performed using repeated measures-2-way ANOVA; Genotype: F(1,24)=0.04, 
p=0.8517; Layer: F(2, 24)=88.12, p<0.0001, no interaction. In each region of 
hippocampus measured for neuronal cells, no significant differences were observed in 
both the Cre- (n=5) and the Cre+  (n=5) female mice. 
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5. DISCUSSION 
 
It has previously been reported that TAK1 is critical for early developement of neuronal 
tube (Shim et al. 2005). Here, we generated transgenic mice that were deficient for 
TAK1 in neurons after birth. Data from our group show that TAK1 plays a role on 
neuronal survival in vitro. The neurons deficient of TAK1 showed higher amount of 
apoptosis than wild-type neurons. Moreover, in vivo studies also showed that TAK1 is 
essential for the survival of different cell types. For instance, epidermal-specific 
deletion of TAK1 leads to massive apoptotic cell death (Omori et al. 2006). TAK1 has 
also an important function for the survival of both hematopoietic cells and hepatocytes 
due to apoptotic cell death observed in TAK1 knockout mice (Tang et al. 2008). Recent 
studies claimed that TAK1 is important for the survival of hepatocytes. Conditional 
ablation of TAK1 in liver parenchymal cells sensitizes hepatocytes to apoptosis as well 
as necrosis (Bettermann et al. 2010). 
In contrast, we did not find any significant difference in the number of neurons between 
both TAK1nko and TAK1 floxed control mice. It is possible that TAK1 might mediate a 
survival signal for many tissue cells, although different cell types may exhibit different 
sensibility to the absence of TAK1.  
Notably, mice lacking TAK1 in liver parenchymal cells showed stronger 
phosphorylation of the other MAP3 kinase TAO2. These mice also exhibit 
hyperactivation of JNK (Bettermann et al. 2010). In line with this study, we cannot 
exclude, that absence of TAK1 in neurons might be compensated by increased 
activation of the other MAP3 kinases. Otherwise, potential increased level of MAP3 
kinases might contribute to increased JNK phosphorylation and pro-survival effect of 
JNK in neurons might be more significant than its pro-apoptotic effect. 
NF-κB is a key regulator of programmed cell death. NF-κB is well known for its anti-
apoptotic function (Barkett and Gilmore 1999; Dutta et al. 2006) as well as for its pro-
apoptotic function (Inta et al. 2006). Thus, survival or fate of cells depends on a defined 
ratio of regulated target genes. Deletion of TAK1 leads to decreased activation of  
NF-κB (Shim et al. 2005) but NF-κB could be activated by other pathways (Senftleben 
et al. 2001). We found, that absence of TAK1 in neurons does not have any significant 
effect on their survival in comparison to control mice. Thus, pro-survival genes in 
neurons may be induced by other pathways of NF-κB, independent on TAK1.  
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It has been shown, that NF-κB plays a role in cerebral ischemia (Ridder and 
Schwaninger 2009), which is one of leading cause of mortality. Therefore, it is 
important to understand the molecular mechanisms of cerebral ischemia. It is also 
important to elucidate the physiological role of each member of the pathways that are 
involved in cerebral ischemia. In this study, we focused on the role of TAK1 in 
neuronal survival. We did not find any significant difference in number of neurons 
between mice that was deficient for TAK1 in neurons and the control group. However, 
we cannot exclude the possibility, that TAK1 plays an important role in neuronal 
survival. Further study may reveal the role of TAK1 in neurons to give us new insights 
into the complex molecular mechanisms of different pathways in the brain. 
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